Introducing Apollo Therapeutics
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
Apollo Portfolio Development
Apollo Therapeutics derives a broad and diversified portfolio through a unique relationship with University of Cambridge, UCL and Imperial College London. This allows confidential access to a wide range of novel biological, translational and clinical research. The Apollo Drug Discovery Team work collaboratively with the academic teams to design and deliver an industry-quality translational research project through to clinical candidate selection.
Diversified current portfolio composition by therapy area
Diversified current portfolio composition by modality
The drug discovery team are highly experienced applied scientists with expertise in the discovery and development of new experimental drugs from a range of modalities and therapeutic indications. The drug discovery team will work with academic scientists from each of the Universities to identify the best translational targets and to prosecute and deliver a pipeline of products for licensing
The investment committee has sole responsibility for reviewing and endorsing the project proposals, plans, costs, timelines and licensing strategy proposed by the drug discovery team
The LLP Committee have responsibility for the management and control of Apollo, including approval of the business plan, the annual budget and the setting of various key governance policies
The Scientific Advisory board will meet annually and advise Apollo on science, portfolio and relevant emerging trends and priorities in the Biopharm and University environments
Apollo Therapeutics News & Press Releases
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm
London, and New York, NY, 21 July 2020 – UCL Business (UCLB) and Apollo Therapeutics (Apollo), a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices, along with Deerfield [...]